Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 15111-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#15111-1-AP, RRID:AB_2155681
- Product name
- NSDHL antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated NSDHL antibody (Cat. #15111-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis.
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.
Hidden disease susceptibility and sexual dimorphism in the heterozygous knockout of Cyp51 from cholesterol synthesis.
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.
Dorsch M, Kowalczyk M, Planque M, Heilmann G, Urban S, Dujardin P, Forster J, Ueffing K, Nothdurft S, Oeck S, Paul A, Liffers ST, Kaschani F, Kaiser M, Schramm A, Siveke JT, Winslow MM, Fendt SM, Nalbant P, Grüner BM
Cell reports 2021 Nov 23;37(8):110056
Cell reports 2021 Nov 23;37(8):110056
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Gabitova-Cornell L, Surumbayeva A, Peri S, Franco-Barraza J, Restifo D, Weitz N, Ogier C, Goldman AR, Hartman TR, Francescone R, Tan Y, Nicolas E, Shah N, Handorf EA, Cai KQ, O'Reilly AM, Sloma I, Chiaverelli R, Moffitt RA, Khazak V, Fang CY, Golemis EA, Cukierman E, Astsaturov I
Cancer cell 2020 Oct 12;38(4):567-583.e11
Cancer cell 2020 Oct 12;38(4):567-583.e11
Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE, Zhang L, Peri S, Kuo YM, Du F, Egleston BL, Ng JMY, Andrews AJ, Astsaturov I, Curran T, Yang ZJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar 15;24(6):1375-1388
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar 15;24(6):1375-1388
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer.
Beck TN, Georgopoulos R, Shagisultanova EI, Sarcu D, Handorf EA, Dubyk C, Lango MN, Ridge JA, Astsaturov I, Serebriiskii IG, Burtness BA, Mehra R, Golemis EA
Molecular cancer therapeutics 2016 Oct;15(10):2486-2497
Molecular cancer therapeutics 2016 Oct;15(10):2486-2497
Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.
Gabitova L, Restifo D, Gorin A, Manocha K, Handorf E, Yang DH, Cai KQ, Klein-Szanto AJ, Cunningham D, Kratz LE, Herman GE, Golemis EA, Astsaturov I
Cell reports 2015 Sep 22;12(11):1927-38
Cell reports 2015 Sep 22;12(11):1927-38
Hidden disease susceptibility and sexual dimorphism in the heterozygous knockout of Cyp51 from cholesterol synthesis.
Lewinska M, Juvan P, Perse M, Jeruc J, Kos S, Lorbek G, Urlep Z, Keber R, Horvat S, Rozman D
PloS one 2014;9(11):e112787
PloS one 2014;9(11):e112787
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.
Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, Egleston BL, Cunningham D, Bagnyukova T, Liu H, Nikonova A, Adams GP, Zhou Y, Yang DH, Mehra R, Burtness B, Cai KQ, Klein-Szanto A, Kratz LE, Kelley RI, Weiner LM, Herman GE, Golemis EA, Astsaturov I
Cancer discovery 2013 Jan;3(1):96-111
Cancer discovery 2013 Jan;3(1):96-111
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 15111-1-AP(NSDHL antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human skin cancer using 15111-1-AP(NSDHL antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The NSDHL antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human NSDHL. This antibody recognizes human,mouse,rat antigen. The NSDHL antibody has been validated for the following applications: ELISA, WB, IHC analysis.
